Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules

Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules

The phosphodiesterase (PDE) enzymes, key regulator of the cyclic nucleotide signal transduction system, are long-established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a particularly high number of clinical trials involving PDE inhibi...

Full description

Bibliographic Details
Main Authors: Andrey D. Bondarev, Misty M. Attwood, Jörgen Jonsson, Vladimir N. Chubarev, Vadim V. Tarasov, Wen Liu, Helgi B. Schiöth
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Pharmacology
Subjects:
PDE inhibition
cyclic nucleotides
second messengers
sildenafil
roflumilast
apremilast
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1057083/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1057083/full

Similar Items